Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

• Status: Unknown status
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avidia

Criteria

Inclusion Criteria:

• Adults 18 - 65

• Stable, moderately active Crohn's Disease

• Otherwise in generally good health

Exclusion Criteria:

• Variety of concurrent medical conditions

• Various concomitant medications